Outgoing Vertex Pharmaceuticals ($VRTX) CEO Matthew Emmens saw his 2011 compensation drop slightly, despite the company's successful launch of its new hepatitis C drug, Incivek. Emmens collected a pay package worth $13.4 million in 2011, down from $14.9 million in 2010. Emmens relinquished the CEO title as of February 1, remaining executive chairman. Report